Molecular Insight Pharmaceuticals, of Cambridge, Mass., appointed Nicholas Borys chief medical officer.
Newron Pharmaceuticals SpA, of Milan, Italy, appointed Rolf Stahel nonexecutive chairman of its board.
Nuevolution A/S, of Copenhagen, Denmark, appointed Knud Aunstrup CEO.
ProtoKinetix Inc., of Vancouver, British Columbia, appointed Jean-Louis Boitieux to its scientific advisory board.
Qualyst Inc., of Research Triangle Park, N.C., appointed Pamela Kirby to its business advisory board.
Quintiles Transnational Corp., of Research Triangle Park, N.C., appointed Dhiraj Narula medical director, integrated cardiac safety services.
Rigel Pharmaceuticals Inc., of South San Francisco, appointed Paul Rodriguez executive vice president and chief operating officer.
Seattle Genetics Inc., of Bothell, Wash., appointed Franklin Berger to its board.
Serenex Inc., of Durham, N.C., appointed Barrie Hesp to its board.
Serologicals Corp., of Atlanta, promoted Chris Park to senior director of North American manufacturing quality assurance.
Sigma-Aldrich Corp., of St. Louis, appointed David Smoller vice president of research and development.
SinusPharma Inc., of Carpinteria, Calif., appointed Robin Campbell president, CEO and a member of its board.
SkinMedica Inc., of Carlsbad, Calif., appointed David Pearson senior vice president of sales and marketing.
Spherics Inc., of Lincoln, R.I., appointed Avinash Nangia vice president of research and development.
Symphogen A/S, of Copenhagen, Denmark, appointed Laurence Jay Korn to its board.
Symyx Technologies Inc., of Santa Clara, Calif., appointed Paul Nowak senior vice president and chief operating officer.
Synta Pharmaceuticals Corp., of Lexington, Mass., appointed Christopher Logothetis, Mace Rothenberg and Daniel Von Hoff to its oncology advisory board. It also appointed John McCarthy senior vice president of corporate development and chief financial officer, and Jeremy Chadwick vice president of program management.
TargeGen Inc., of San Diego, appointed Sara Courtneidge to its scientific advisory board.
Thios Pharmaceuticals Inc., of Emeryville, Calif., named Elizabeth Squiers vice president of clinical development.
Transkaryotic Therapies Inc., of Cambridge, Mass., named Marcio Voloch vice president of process development.
Tranzyme Pharma, of Research Triangle Park, N.C., elected Daniel Veber and Jean-Paul Castaigne to its board.
Trillium Therapeutics Inc., of Toronto, appointed Marc Feldmann to its scientific advisory board.
Varian Inc., of Palo Alto, Calif., appointed Sean Wirtjes controller.
Vical Inc., of San Diego, appointed Robin Jackman vice president of business development.
Viral Genetics, of Azusa, Calif., appointed Eric Rosenberg to its scientific and medical advisory board.